Beam Therapeutics has entered into a collaboration agreement with Pfizer to advance new in vivo genome base editing programs for rare genetic diseases of the liver, muscle and central nervous system. Beam will conduct all research activities, and Pfizer will be able to select exclusive worldwide licenses for each of the three candidate candidates at a total cost of up to $1.35 billion, after which it will be responsible for all development activities as well as the regulatory approvals and commercialization of each such candidate.